Monograph Capital

Monograph Capital is a London-based venture capital firm dedicated to advancing groundbreaking life sciences companies, aiming to transform promising scientific innovations into impactful, life-changing treatments globally. The firm focuses on early-stage investments in biotechnology, pharmaceuticals, medical devices, and digital health sectors, providing critical capital, strategic guidance, and industry expertise to drive the development and success of its portfolio companies.

The firm's investment strategy emphasizes identifying and supporting innovative companies and technologies that aim to advance healthcare and biotechnology. Monograph Capital's team comprises M.D.s and PhDs with decades of experience in biomedical research, clinical medicine, and digitally-enabled health services, operating across North America and Europe. This expertise enables the firm to bridge opportunities across these regions, bringing deep experience, assets, and capabilities to help life sciences companies scale and succeed.

Through its strategic investments, Monograph Capital plays a crucial role in accelerating innovation and improving health outcomes globally. The firm's portfolio includes companies such as AviadoBio, Maxion Therapeutics, Nocion Therapeutics, and Sudo, reflecting its commitment to supporting transformative healthcare solutions. By partnering with young companies and scientific entrepreneurs, Monograph Capital contributes to the development of novel research, therapies, diagnostics, and digital innovations that lead to better healthcare outcomes.